Background: The sympathetic block of upper limb leading to increased blood flow has important clinical implication in microvascular surgery. However, little is known regarding the relationship between concentration of local anesthetic and blood flow of upper limb. The aim of this dose-response study was to determine the ED and ED of ropivacaine in blood flow after supraclavicular block (SB).
Methods: Patients undergoing upper limb surgery and supraclavicular block were randomly assigned to receive 30ml ropivacaine in concentrations of 0.125%(A Group), 0.2%(B Group), 0.25%(C Group), 0.375%(D Group), 0.5%(E Group), or 0.75%(F Group) (n=13 per group). All patients received supraclavicular block (SB). Time average maximum velocity (TAMAX), cross-sectional area (CSA) of brachial artery and skin temperatures (T) were measured repeatedly at the same marked points, they were taken at baseline (before block, t) and at 30min after SB (t). Blood flow(BF) = TAMAX× CSA×60 sec.. Relative blood flow (ΔBF) = BF/ BF. Success of SB was assessed simultaneously. Supplementary anesthesia and other adverse events (AE) were recorded.
Results: Significant increase in TAMAX, CSA, BF and T were seen in all concentration groups at t comparing with t (P<0.001). There was an upward trend of TAMAX, CSA, BF with the increasing concentration of ropivacaine except T. There was no significant different of T at t among different concentration group. The dose-response formula of ropivacaine on ΔBF was Y=1+3.188/(1+10^((-2.451-X) × 1.730)) and ED/ED (95%CI) were 0.35/1.94%(0.25-0.45/0.83-4.52), and R (coefficient of determination) =0.85. ED/ED (95%CI) values of sensory block were 0.18/0.33% (0.15-0.21/0.27-0.51), R=0.904.
Conclusions: The dose-response curve between SB ropivacaine and the changes of BF was determined. The ED/ED of ropivacaine of ΔBF are 0.35/1.94% (0.25-0.45/0.83-4.52). TAMAX, CSA and BF consistently increased with ropivacaine concentration. The maximal sympathetic block needs higher concentration than that complete sensation block needs which may benefit for microvascular surgery.
Trial Registration: Clinicaltrials.gov NCT02139982 . Retrospectively registered (Date of registration: May, 2014).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5712185 | PMC |
| http://dx.doi.org/10.1186/s12871-017-0447-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Murine Aortic Valve Cell Heterogeneity at Birth.
Arterioscler Thromb Vasc Biol
March 2025
Department of Pediatrics, Division of Pediatric Cardiology, Medical College of Wisconsin, Milwaukee (T.B., J.R.K., A.J.K., J.L.).
Background: Heart valve function requires a highly organized ECM (extracellular matrix) network that provides the necessary biomechanical properties needed to withstand pressure changes during each cardiac cycle. Lay down of the valve ECM begins during embryogenesis and continues throughout postnatal stages when it is remodeled into stratified layers and arranged according to blood flow. Alterations in this process can lead to dysfunction and, if left untreated, heart failure.
View Article and Find Full Text PDFSignificance: Coronary artery disease is the leading cause of death worldwide, accounting for 16% of all deaths. A common treatment is coronary artery bypass grafting (CABG), though up to 12% of bypass grafts fail during surgery. Early detection of graft failure by intraoperative graft patency assessment could prevent severe complications.
View Article and Find Full Text PDFMultiparameter flow cytometric and transcriptional analyis of CD20 positive T-cells in bone marrow in patients of multiple myeloma and monoclonal gammopathy of undetermined significance.
Front Immunol
March 2025
Department of Pathology, University of Pécs Medical School, Clinical Centre, Pécs, Hungary.
Introduction: CD20+ T-cells were described firstly in peripheral blood and later in bone marrow in patients with hematological tumors, and certain immune-mediated diseases. During our hematological diagnostic work, this peculiar subgroup of lymphocytes has been consistently observed associated with untreated monoclonal gammopathy of undetermined significance (MGUS) and myeloma (MM). Despite the expanding literature data, the exact function of CD20+ T cells remains unclear.
View Article and Find Full Text PDFMaplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy.
Front Immunol
March 2025
Pfizer Oncology, Pfizer Inc., La Jolla, CA, United States.
Introduction: CD47 is highly expressed on cancer cells and triggers an anti-phagocytic "don't eat me" signal when bound by the inhibitory signal regulatory protein α (SIRPα) expressed on macrophages. While CD47 blockade can mitigate tumor growth, many CD47 blockers also bind to red blood cells (RBCs), leading to anemia. Maplirpacept (TTI-622, PF-07901801) is a CD47 blocking fusion protein consisting of a human SIRPα fused to an IgG4 Fc region and designed to limit binding to RBCs.
View Article and Find Full Text PDFReal-time organ perfusion monitoring of human kidney transplants using normothermic perfusion and reflectance spectroscopy.
R Soc Open Sci
March 2025
Interface Analysis Centre, HH Wills Physics Laboratory, School of Physics, University of Bristol, Bristol, UK.
Transplantation is the standard treatment for end-stage kidney disease but carries with it a non-trivial risk of post-operative complication. There is a need for a continuous, real-time, not additionally invasive method of monitoring organ perfusion. We present an approach to allograft perfusion monitoring using a human kidney model using normothermic perfusion (EVNP) and custom spectroscopic optical reflectance probes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!